CROMWELL, Conn.--(BUSINESS WIRE)--Biological Industries USA (BI-USA), a division of Biological Industries Israel LTD, announced today a distribution agreement with Mill Creek Life Sciences LLC, a Rochester, Minnesota start-up that provides tools to support the development and application of cellular and biological therapeutics. The agreement provides for distribution of PLTMax® Human Platelet Lysate, a product derived from human platelets and offers unparalleled cell growth and cytogenetic stability of adult stem cells over fetal bovine serum (FBS). PLTMax® is available in research and clinical grades and has been used in more than 30 clinical trials worldwide, including several Phase III trials.
“We are very pleased to announce our partnership with the team at Mill Creek Life Sciences,” said Tanya Potcova, Chief Executive Officer of BI-USA. “We have a great opportunity to expand our stem cell portfolio reach here in the US and beyond. We met with Mill Creek at the Cell & Gene Meeting on the Mesa in San Diego last October, where we discussed the potential use of PLTMax® with our xeno-free NutriStem® MSC Medium and EndoGo™ XF Medium. We found that we have a mutual interest in serving the needs of the stem cell industry through application development by pairing our leading technology together for use in both research and clinical development. We are excited about the potential for us to expand this collaboration.”
“Mill Creek Life Sciences is happy to announce this relationship with Biological Industries,” said Bill Mirsch, Chief Executive Officer of Mill Creek Life Sciences. “We tested their NutriStem® MSC Medium and EndoGo™ XF Medium and found them to be very effective when paired with our PLTMax®. We look forward to partnering with BI-USA to provide the best research and GMP grade media options for MSC and endothelial cell therapies.”
About Biological Industries
Biological Industries (www.bioind.com) is one of the world’s leading and trusted suppliers to the life sciences industry, with over 35 years’ experience in cell culture media development and GMP manufacturing. BI’s products range from classical cell culture media to supplements and reagents for stem cell research and potential cell therapy applications, to serum-free media and many other products for animal cell culture and molecular biology. BI is committed to a Culture of Excellence through advanced manufacturing and quality-control systems, regulatory expertise, in-depth market knowledge, and extensive technical customer-support, training, and R&D capabilities.
Biological Industries USA (BI-USA) is the US commercialization arm of BI, with facilities in Cromwell, Connecticut. Members of the BI-USA team share a history and expertise of innovation and success in the development of leading-edge technologies in stem cell research, cellular reprogramming, and regenerative medicine.
About Mill Creek Life Sciences
Mill Creek Life Sciences (www.millcreekls.com) is the first company to commercialize human platelet lysate for cellular therapy. A spin-off out of the Human Cell Therapy Laboratory at the Mayo Clinic in Rochester, Minnesota, Mill Creek has been involved in clinical cellular therapies from the beginning. Mill Creek is dedicated to providing the highest quality products for the research and clinical community.